TY - JOUR. T1 - Flares in pediatric systemic lupus erythematosus. AU - Weiss, Jennifer E.. AU - Sison, Cristina P.. AU - Ilowite, Norman T.. AU - Gottlieb, Beth S.. AU - Eberhard, Barbara A.. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Objective. To determine the flare rate and the change in Safety of Estrogens in Lupus Erythematosus: National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) score with disease flare in pediatric systemic lupus erythematosus (pSLE). Methods. A retrospective chart review of 62 patients with pSLE (ages 5-20 yrs). A flare was defined as the start of, or increase in, the dose of corticosteroids and/or the addition of an immunosuppressive medication. All pre-flare, flare, and post-flare visits were recorded with a SELENA SLEDAI score calculated for each visit. The flare rate was calculated by dividing the total number of flares in the cohort by the total followup years. Results. Sixty-two patients were eligible. Forty-seven patients had 112 ...
OBJECTIVE: To describe the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), a modification of SLEDAI to reflect persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences, and to validate SLEDAI-2K against the original SLEDAI as a predictor for mortality and as a measure of global disease activity in the clinic. METHODS: All visits in our cohort of 960 patients were used to correlate SLEDAI-2K against the original SLEDAI, and the whole cohort was used to validate SLEDAI-2K as a predictor of mortality. A subgroup of 212 patients with SLE followed at the Lupus Clinic who had 5 regular visits, 3-6 months apart, in 1991-93 was also included. An uninvolved clinician evaluated each patient record and assigned a clinical activity level. The SLEDAI score was calculated from the database according to both the original and modified definitions. RESULTS: SLEDAI-2K correlated highly (r = 0.97) with SLEDAI. Both methods for SLEDAI ...
Patients with the autoimmune disease systemic lupus erythematosus (SLE) develop pathogenic antibodies against their own self-antigens. U1-70(131-150):I-Ek (without phosphorylation) correlates with disease intensity and antiCU1-70 autoantibody creation. These T cells express RORt and produce IL-17A also. Furthermore, the U1-70Cparticular Compact disc4+ T cells that generate IL-17A are discovered within a subset of sufferers Dovitinib with SLE and so are significantly elevated in sufferers with blended connective tissues disease. These scholarly research offer equipment for learning antigen-specific POLDS Compact disc4+ T cells in lupus, and show an Dovitinib antigen-specific way to obtain IL-17A in autoimmune disease. Systemic lupus erythematosus (SLE) can be an autoimmune disease where sufferers develop high-titer, specific highly, isotype-switched autoantibodies against DNA- and RNA- filled with autoantigens (1). U1-70, U1-A, and U1-C, with U1-RNA as well as the seven Smith proteins jointly, ...
OBJECTIVES: To perform systematic assessment of ovarian reserve markers using a combination of tests in juvenile systemic lupus erythematosus (JSLE) patients without amenorrhoea. METHODS: Twenty-seven consecutive JSLE female patients and 13 healthy c
Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti-double-stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. ...
Clinical trial for SYSTEMIC LUPUS ERYTHEMATOSUS , Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
LU, Zhimin et al. Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections. Braz J Med Biol Res [online]. 2019, vol.52, n.4, e8131. Epub 15-Abr-2019. ISSN 1414-431X. https://doi.org/10.1590/1414-431x20198131.. The leading cause of death in systemic lupus erythematosus (SLE) patients is infection. The objective of this study was to evaluate the distribution of lymphocyte subsets in untreated SLE patients with infections. This was a cross-sectional study. Data from January 2017 to May 2018 were collected. Flow cytometry was used to measure the peripheral lymphocyte subsets including CD3+T cells, CD4+T cells, CD8+T cells, CD19+B cells, CD3-CD16+CD56NK cells, and CD3+CD16+CD56NKT cells in 25 healthy controls and 52 treatment-naive SLE patients, among whom 13 were complicated with infections. Association between the lymphocyte subsets and infections was further analyzed. SLE patients with infections (n=13) showed a significantly higher incidence rate of ...
OBJECTIVE: To determine the impact of the patients sex on the manifestations and outcome of systemic lupus erythematosus (SLE).. METHODS: We studied SLE patients who were ages 16 years or older and had a disease duration of , or =5 years at the time of enrollment in the LUpus in MInorities, NAture versus nurture cohort, a multiethnic cohort consisting of Hispanic, African American, and Caucasian patients. Socioeconomic/demographic, clinical, and serologic features, as well as disease activity (by the Systemic Lupus Activity Measure, Revised) and damage accrual (by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) were compared between male and female patient groups. Multivariable analyses using male sex and damage accrual as dependent variables were then performed.. RESULTS: Sixty-three male SLE patients (10.2%) from all ethnic groups were included. The mean ages of the male and female patients were comparable. Factors that were either more ...
TY - JOUR. T1 - Possible triggering effect of cytomegalovirus infection on systemic lupus erythematosus. AU - Nawata, M.. AU - Seta, N.. AU - Yamada, M.. AU - Sekigawa, I.. AU - Iida, N.. AU - Hashimoto, H.. PY - 2001. Y1 - 2001. N2 - We report on a patient with systemic lupus erythematosus (SLE) who showed elevated titers of IgM antibodies to cytomegalovirus (CMV), suggesting CMV infection at the onset of SLE. Serum CMV antigens were also detected in the patient. These findings raise the possibility that CMV infection may be related to the onset of SLE in certain patients.. AB - We report on a patient with systemic lupus erythematosus (SLE) who showed elevated titers of IgM antibodies to cytomegalovirus (CMV), suggesting CMV infection at the onset of SLE. Serum CMV antigens were also detected in the patient. These findings raise the possibility that CMV infection may be related to the onset of SLE in certain patients.. KW - Cytomegalovirus. KW - Proteinuria. KW - Systemic lupus ...
Immunoglobulin M (IgM) autoreactivity to malondialdehyde (MDA) protein modifications is part of the natural antibody repertoire in health and may have beneficial functions. In contrast, IgG anti-MDA are increased in chronic inflammation and autoimmunity and may instead have pathogenic properties. Herein, we investigated serum IgG anti-MDA levels by enzyme-linked immunosorbent assay (ELISA) in 398 systemic lupus erythematosus (SLE) patients in the Swedish Karolinska SLE cohort and compared these to findings in 225 US SLE patients from New York University and Johns Hopkins University. In two independent cohorts, IgG anti-MDA levels correlated positively with disease activity by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; p | 0.0001, Spearman R = 0.3). Meta-analysis found an odds ratio of 2.7 (confidence interval (CI) 1.9-3.9; p | 0.0001) for high anti-MDA IgG levels with active disease (SLEDAI ≥ 6). Furthermore, IgG anti-MDA correlated directly with erythrocyte sedimentation rate
An SRI response is defined as a reduction from baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) score of at least 4 points, no worsening in Physicians Global Assessment (PhGA) (with worsening defined as an increase in PhGA of more than 0.30 point from baseline), no British Isles Lupus Assessment Group A (BILAG A) organ domain score, and no more than 1 new BILAG B organ domain score from baseline ...
Systemic lupus erythematosus: Find the most comprehensive real-world symptom and treatment data on systemic lupus erythematosus at PatientsLikeMe. 37842 patients with systemic lupus erythematosus experience muscle pain, joint swelling, skin sensitivity to sun (photosensitivity), joint pain, and chest pain and use Hydroxychloroquine, Prednisone, Methotrexate, Belimumab, and Azathioprine to treat their systemic lupus erythematosus and its symptoms.
Both systemic lupus erythematosus (SLE) and its treatment can cause immunosuppression and a decreased response to vaccination. We evaluated 30 children and adolescents with SLE, and 14 age-matched healthy subjects (control group) regarding immunophenotyping and lymphocyte apoptosis by flow cytometry
TY - JOUR. T1 - Delineation of the human systemic lupus erythematosus anti-Smith antibody response using phage-display combinatorial libraries. AU - Del Rincon, I.. AU - Zeidel, M.. AU - Rey, E.. AU - Harley, J. B.. AU - James, J. A.. AU - Fischbach, M.. AU - Sanz, I.. PY - 2000/12/15. Y1 - 2000/12/15. N2 - The anti-Smith (Sm) autoantibody response is highly specific for systemic lupus erythematosus and is predominantly targeted to the Sm-B/B and -D1 polypeptides. In all animal species thus far studied, anti-Sm Abs initially recognize proline-rich epitopes in the carboxyl terminus of the Sm-B/B protein and subsequently to multiple other epitopes in B/B and D. The absence of appropriate mAbs has limited our understanding of the genetic and structural basis of this autoimmune response. Using phage-display technology and lymphocytes from a systemic lupus erythematosus patient we have generated the first and only panel of human IgG anti-Sm mAbs thus far available. These Abs reproduced to a ...
Results The serum levels of sCXCL16 in jSLE patients were higher than controls (p,0.001), they were also siginificantly higher in patients with alopecia or malar rash than other jSLE .Positive correlation was identified between serum levels of sCXCL16 and SLEDAI score. There was a significant positive correlation between sCXCL16 levels and severity of lupus nephritis as assessed by renal biopsy. Serum levels of sCXCL16 were positively significantly correlated with the 24 hour urine protein,ANA, SBP, DBP AND ESR 1st hour. Serum sCXCL16 level was significanly negatively correlated with C3 serum level. ...
Global Glucocorticoid for Systemic Lupus Erythematosus Status and Trend Report offers a comprehensive analysis of Glucocorticoid for Systemic Lupus Erythematosus industry, standing on the readers perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.. The Asia-Pacific will occupy more market share in the following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes from the United States might affect the development trend of Glucocorticoid for Systemic Lupus Erythematosus. Europe also plays important roles in the global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%. This report studies the Glucocorticoid for Systemic Lupus Erythematosus market status and ...
View more ,Periodontal disease is a group of chronic inflammatory diseases affecting tooth-supporting tissues. The early stage is the presence of biofilm-associated gingival inflammation which, in patients having juvenile systemic lupus erythematosus (SLE), might function as a reservoir of anaerobic Gram-negative bacteria such as Porphyromonas gingivalis. Porphyromonas gingivalis has been associated with an increased level of anticardiolipin and anti-b2-glycoprotein antibodies in patients with SLE, which implies periodontal disease as a modifiable risk factor for SLE morbility1 . Besides, Porphyromonas gingivalis also express functional endogenous Peptidylarginine deiminase (PAD) enzymes, which catalyzes a citrullination reaction that can lead to formation of citrullinated peptides. PAD can frequently be recognized in sera of patients with rheumatoid arthritis, systemic lupus erythematosusand primary Sjögren syndrome2 . Laugisch et al. 3 reported that PAD secreted by Porphyromonas gingivalis ...
Autoantibodies against complement C1q (anti-C1q Abs) were shown to strongly correlate with the occurrence of severe nephritis in patients with systemic lupus erythematosus (SLE), suggesting a potential pathogenic role by interfering with the complement cascade. To analyze the humoral immune response against C1q at the molecular level, we screened a bone marrow-derived IgGkappa/IgGlambda Fab phage display library from a SLE patient with high anti-C1q Ab titer against purified human C1q. Six Fabs that exhibited strong binding to C1q in ELISA were isolated. The anti-C1q Fabs recognized neoepitopes that were only exposed on bound C1q and not present on soluble C1q mapping to different regions of the collagen-like region of C1q. Analysis of the genes encoding the variable H and L chains of the IgG-derived anti-C1q Fab revealed that all the variable H and L chain regions were highly mutated, with nucleotide and amino acid homologies to the closest germline in the range of 71-97% (average 85 +/- 4) and ...
TY - JOUR. T1 - Cardiac pathology of systemic lupus erythematosus. AU - Jain, D.. AU - Halushka, Marc K. PY - 2009/7. Y1 - 2009/7. N2 - Systemic lupus erythematosus is a common chronic autoimmune disorder causing injury to many organ systems. Cardiac complications of lupus affect most parts of the heart. These include pericarditis, myocarditis, endocarditis and coronary artery disease. While many histopathological findings in lupus-related cardiac diseases are non-specific, there are a few important findings which pathologists should be aware of. This review provides pathological descriptions of these entities.. AB - Systemic lupus erythematosus is a common chronic autoimmune disorder causing injury to many organ systems. Cardiac complications of lupus affect most parts of the heart. These include pericarditis, myocarditis, endocarditis and coronary artery disease. While many histopathological findings in lupus-related cardiac diseases are non-specific, there are a few important findings which ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Results The mean age of the JSLE children was 13.25±2.09 years and 23.17±4.26 years for JO-SLE cases. JO-SLE cases were older at disease onset with a higher female-to-male ratio. There were no noticeable gender differences. There was a significantly higher frequency of serositis, nephritis and hematological involvement in the JO-SLE (57.7%, 76.9% and 73.1%) compared to the JSLE cases (15.4%; 30.8% and 30.8%) (p,0.001 for all). The erythrocyte sedimentation rate, creatinine and proteinuria were significantly increased in JO-SLE while alkaline phosphatase was higher in JSLE cases. In JO-SLE cases, SLEDAI significantly increased (5.96±6.18 vs 3.12±1.97; p=0.003) and the SLICC tended to increase compared to the JSLE children. More JO-SLE cases received hydroxychloroquine and azathioprine. ...
Fanouriakis A, Kostopoulou M, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-745. Systemic lupus erythematosus (lupus). National Institute of Arthritis and Musculoskeletal and Skin Diseases website. Available at: http://www.niams.nih.gov/Health%5FInfo/Lupus/default.asp. Accessed January 8, 2021. Systemic lupus erythematosus (SLE). EBSCO DynaMed website. Available at: https://www.dynamed.com/condition/systemic-lupus-erythematosus-sle. Accessed January 8, 2021. Understanding lupus. Lupus Foundation of America website. Available at: http://www.lupus.org/answers/topic/understanding-lupus. Accessed January 8, 2021. ...
Amital H, Szekanecz Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010 Jun;69(6):1155-7. (Epub ahead of print). Bast A, Haenen GR. Lipoic acid: a multifunctional antioxidant. Biofactors. 2003;17(1-4):207-13.. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov;46(11):2924-7.. Costenbader KH, Kang JH, Karlson EW. Antioxidant Intake and Risks of Rheumatoid Arthritis and Systemic Lupus Erythematosus in Women. Am J Epidemiol. 2010 Jun 9. [Epub ahead of print]. Dryden GW Jr, Deaciuc I, Arteel G, McClain CJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep. 2005;7(4):308-16.. El-Badri NS, Hakki A, Ferrari ...
Is melasma a symptom of systemic lupus erythematosus sle - Is there a cure for systemic lupus erythematosus (sle)? SLE treatment. Systemic lupus erythematosus (sle) is a long-term autoimmune disorder that may affect the skin, joints, kidneys, brain, and other organs. There is no cure for sle. The goal of treatment is to control symptoms.
Arntfield RT, Hicks CM. Systemic lupus erythematosus and the vasculitides. In: Walls RM, Hockberger RS, Gausche-Hill M, eds. Rosens Emergency Medicine: Concepts and Clinical Practice. 9th ed. Philadelphia, PA: Elsevier; 2018:chap 108.. Crow MK. Etiology and pathogenesis of systemic lupus erythematosus. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, ODell JR, eds. Kelley and Firesteins Textbook of Rheumatology. 10th ed. Philadelphia, PA: Elsevier; 2017:chap 79.. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6) :736-745. PMID: 30926722 pubmed.ncbi.nlm.nih.gov/30926722/.. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808. PMID: 22556106 pubmed.ncbi.nlm.nih.gov/22556106/.. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target ...
Systemic lupus erythematosus (SLE) is a rheumatic disease characterized by autoantibodies directed against self-antigens, immune complex formation, and immune dysregulation, resulting in damage to essentially any organ. The disease can affect, for example, the kidneys, skin, blood cells, and nervous system.
Table of Contents. Table of Contents 2. List of Tables 7. List of Figures 9. Introduction 10. Global Markets Direct Report Coverage 10. Systemic Lupus Erythematosus Overview 11. Therapeutics Development 12. Pipeline Products for Systemic Lupus Erythematosus-Overview 12. Pipeline Products for Systemic Lupus Erythematosus-Comparative Analysis 13. Systemic Lupus Erythematosus-Therapeutics under Development by Companies 14. Systemic Lupus Erythematosus-Therapeutics under Investigation by Universities/Institutes 19. Systemic Lupus Erythematosus-Pipeline Products Glance 20. Late Stage Products 20. Clinical Stage Products 21. Early Stage Products 22. Unknown Stage Products 23. Systemic Lupus Erythematosus-Products under Development by Companies 24. Systemic Lupus Erythematosus-Products under Investigation by Universities/Institutes 29. Systemic Lupus Erythematosus-Companies Involved in Therapeutics Development 30. 4SC AG 30. AbbVie Inc. 31. Ablynx NV 32. Actelion Ltd 33. AiCuris GmbH & Co. KG 34. Amgen ...
TY - JOUR. T1 - Echocardiographic observation of acute myocarditis with systemic lupus erythematosus. AU - Ueda, Takashi. AU - Mizushige, Katsufumi. AU - Aoyama, Tohru. AU - Tokuda, Michiaki. AU - Kiyomoto, Hideyasu. AU - Matsuo, Hirohide. PY - 2000/2/1. Y1 - 2000/2/1. N2 - Although myocarditis from a series of autopsies of patients with systemic lupus erythematosus was frequently observed, the incidence of clinically apparent myocardial dysfunction was low. A 30-year-old woman with systemic lupus erythematosus was examined by echocardiography. An acoustic densitometry was followed at the left ventricular posterior wall throughout the clinical course. A decrease in the magnitude of cyclic variation of integrated backscatter (IB) was observed before treatment. Following the combined treatment, steroid and cyclophosphamide, a repeated ultrasonic tissue characterization showed an increase in the magnitude of cyclic variation of IB. It is thought that ultrasonic tissue characterization may be a ...
Systemic lupus erythematosus Bluish complexion, Bluish skin, Blue-tinge to the skin, Cough with cloudy, fishy-smelling mucus, Cough with cloudy, fishy-smelling sputum, , Chronic constipation (elderly people), , systemic lupus erythematosus
Get information, facts, and pictures about Systemic Lupus Erythematosus at Encyclopedia.com. Make research projects and school reports about Systemic Lupus Erythematosus easy with credible articles from our FREE, online encyclopedia and dictionary.
The purpose of the present study was to compare dynamic muscle strength, functional performance, fatigue, and quality of life in premenopausal systemic lupus erythematosus (SLE) patients with low disease activity versus matched-healthy controls and to determine the association of dynamic muscle strength with fatigue, functional performance, and quality of life in SLE patients. We evaluated premenopausal (18-45 years) SLE patients with low disease activity (Systemic lupus erythematosus disease activity index [SLEDAI]: mean 1.5 ± 1.2). The control (n = 25) and patient (n = 25) groups were matched by age, physical characteristics, and the level of physical activities in daily life (International Physical Activity Questionnaire IPAQ). Both groups had not participated in regular exercise programs for at least six months prior to the study. Dynamic muscle strength was assessed by one-repetition maximum (1-RM) tests. Functional performance was assessed by the Timed Up and Go (TUG), in 30-s test a chair stand
To explore the inadequacies of health service and its impact on clinical outcomes of patients with systemic lupus erythematosus (SLE) in China. A total of 210 SLE patients were randomly recruited between January 2017 and January 2018. Each patient received self-report questionnaires to assess medication adherence [Compliance Questionnaire for Rheumatology (CQR)], beliefs about medicines [Beliefs about Medicines Questionnaire (BMQ)] and satisfaction about medicine information [the Satisfaction with Information about Medicines Scale (SIMS)]. Associations between SLE disease activity index (SLEDAI-2 K) and observed factors were analyzed by multiple logistic regression. Based on CQR, only 28.10% patients were adherent. The score of BMQ was 2.85 ± 5.42, and merely 32.38% patients were satisfied with the information about their prescribed medicines. Disease activity was associated with SIMS, EuroQol five-dimensions [EQ5D], Systemic Lupus International Collaborating Clinics (SLICC), depression, use of NSAID
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that significantly affects health-related quality of life (HRQOL): physical, psychologic, mental, and social aspects of well-being that are influenced by disease, in the context of life experiences and expectations specific to each patient1. A relapsing, remitting chronic disease, SLE results in disability in 20%-40% of afflicted young and middle-aged women and men2. In patients with SLE, HRQOL is influenced by disease activity and symptoms of fatigue, depression, pain, sleep disturbances, and cognitive dysfunction3. Across 5 randomized controlled trials (RCT) in SLE, baseline HRQOL scores were low and were similar to those of subjects following myocardial infarction or with chronic congestive heart failure4. Lower scores were highly correlated with history of renal disease, presence of anti-dsDNA antibodies, higher disease activity scores by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and/or Safety of ...
Group A only: patients on immunosuppressive treatments had them withdrawn at baseline. All patients were allowed up to 160 mg depomedrol at baseline which could be repeated within two weeks up to a total of 4 shots maximum or until satisfactory improvement. Time to flare was calculated from baseline. moderate disease at baseline was defined as up to 3 BILAG B (moderate disease) organ scores, no BILAG A (severe disease) score and a SLEDAI ,/= 10. Severe disease required ,3 BILAG B, OR at least one BILAG A OR SLEDAI , 10 or meeting criteria for a severe flare on the SELENA SLEDAI flare index. At baseline 25 patients with moderate disease. 16 patients had severe disease. Note: severe rash with A on BILAG is only SLEDAI=2, explaining some discrepancies in measures ...
Keywords: Panretinal photocoagulation Retinal vascular occlusion Systemic lupus erythematosus Intro Systemic lupus erythematosus can be a multisystem disease of unfamiliar etiology seen as a several autoimmune phenomena with lesions in multiple body organ systems. Ocular manifestations of systemic BML-275 lupus erythematosus (SLE) consist of mucocutaneous involvement from the eyelids supplementary Sjogrens symptoms optic neuropathy. The retinopathy includes cotton wool spots with or without retinal hemorrhages generally.1-3 Vaso-occlusive disease particularly in the current presence of antiphospholipid antibodies usually trigger devastating and long term damage to visible function regardless of strenuous treatment and requires treatment with anticoagulation and proliferative retinopathy is treated with laser beam therapy.2 3 Case record A 35-year-old female was admitted due to sudden loss of visual acuity in the still left attention. She have been diagnosed as experiencing systemic lupus ...
Introduction: Patients with systemic lupus erythematosus (SLE) are at increased risk of metabolic syndrome (MetS) and its complications. In absence of..
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disease. Genome-wide association studies (GWAS) have identified multiple risk SNPs in HLA and non-HLA gene regions. There is evidence that genetics are also important in lupus nephritis (LN) risk. LN is one of the most common and severe manifestations of SLE. The purpose of this study was to determine the association of known SLE risk SNPs with LN in both childhood-onset (cSLE) and adult-onset SLE (aSLE) populations. Methods: The study population included two tertiary care SLE cohorts; one with cSLE and the other with aSLE. Participants met American College of Rheumatology (ACR) and/or Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE, with prospectively collected clinical and laboratory data. Participants were genotyped on the Illumina MEGA or Omni1 arrays. Principal components were calculated in reference to the 1000 genomes project, and ancestry was genetically ...
This paper will explore juvenile Systemic Lupus Erythematosus. It will also explore its signs, symptoms, diagnosis, prognosis, statistics, treatment, complications, risk factors, and diet.
Objective(s): Apoptosis is a tightly regulated process and plays a crucial role in autoimmune diseases. Because abnormalities in apoptosis are considered to be involved in the pathogenesis of systemic lupus erythematosus (SLE), in present study we studied the apoptosis in T lymphocytes from Iranian SLE patientsat protein and gene expression levels for some molecules which are involved in apoptosis pathways. Materials and Methods: Thirty five SLE patients (23 female, 12 male), and 20 age matched controls (10 female, 10 male) participated in this study. T lymphocytes were isolated from peripheral blood mononuclear cells (PBMCs) using MACS method. Apoptosis rate was studied at protein level by flow cytometer using Annexin V, and at gene expression level using semi-quantitative RT-PCR method for detection of Fas, FasL, Bcl-2, caspase 8, and caspase 9 genes. Results: The percentage of apoptotic cells in SLE patients was not different in comparison with controls (20.2% ± 1.4 vs 21.1% ± 1.0), but the
TY - JOUR. T1 - Genetic ancestry, serum interferon- αactivity, and autoantibodies in systemic lupus erythematosus. AU - Ko, Kichul. AU - Franek, Beverly S.. AU - Marion, Miranda. AU - Kaufman, Kenneth M.. AU - Langefeld, Carl D.. AU - Harley, John B.. AU - Niewold, Timothy B.. PY - 2012/6. Y1 - 2012/6. N2 - Objective. To investigate and refine the relationships among systemic lupus erythematosus (SLE) and related autoantibodies, interferon-α (IFN-α), and various ancestral backgrounds. Methods. We investigated quantitatively defined genetic ancestry through principal component analysis in place of self-reported ancestry. Results. African ancestry was found to be associated with presence of anti-RNP antibody (p = 0.0026), and anti-RNP was correlated with high levels of IFN-α (p = 2.8 × 10 -5). Conclusion. Our data support a model in which African ancestry increases the likelihood of SLE-associated autoantibody formation, which subsequently results in higher levels of serum IFN-α. The Journal ...
Data abstracted retrospectively from the charts at 11,359 clinic visits for 310 patients with SLE to the Montreal General Hospital were used to investigate the associations of recent corticosteroid dose and recent Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with 8 CHD risk factors (total serum cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein cholesterol, apolipoprotein B [Apo B], triglycerides, systolic blood pressure [BP], body mass index, and blood glucose) and the aggregate estimate of 2-year CHD risk. Separate multivariable linear regression models estimated the mutually-adjusted effects of average daily corticosteroid dose and average SLEDAI score within the past year on the current level of each risk factor while adjusting for age, sex, cumulative damage score, disease duration, and, where appropriate, use of relevant medications ...
Introduction Systemic Lupus Erythematosus (SLE) shows a spectrum of clinical manifestations that complicate its diagnosis, treatment and research. This variability is likely related with environmental exposures and genetic factors among which known SLE susceptibility loci are prime candidates. The first published analyses seem to indicate that this is the case for some of them, but results are still inconclusive and we aimed to further explore this question. Methods European SLE patients, 1444, recruited at 17 centres from 10 countries were analyzed. Genotypes for 26 SLE associated SNPs were compared between patients with and without each of 11 clinical features: ten of the American College of Rheumatology (ACR) classification criteria (except ANAs) and age of disease onset. These analyses were adjusted for centre of recruitment, top ancestry informative markers, gender and time of follow-up. Overlap of samples with previous studies was excluded for assessing replication. Results There were three
The Janssen Pharmaceutical Companies of Johnson & Johnson presented this week results of two analyses from a Phase 2 study of Stelara®*(ustekinumab) in systemic lupus erythematosus (SLE). The studies highlight not only the sustained clinical benefit of ustekinumab - an anti-interleukin (IL) IL-12/23 p40 neutralising monoclonal antibody - on SLE disease activity at one-year, but also show a reduction in the rate of severe flares.. They also provide new insights into the possible pathway through which ustekinumab is acting in SLE patients who respond to IL-12/23 p40 blockade.1,2. The Phase 2 study, presented by lead study investigator Ronald van Vollenhoven MD PhD and colleagues, is a global randomized, placebo-controlled trial in 102 adults with seropositive SLE by Systemic Lupus International Collaborating Clinics (SLICC) criteria and active disease despite ongoing standard of care therapy (steroid, antimalarial and/or immunosuppressive therapies).1Patients were randomized (3:2) to receive ...
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by production of autoantibodies and immune complex deposition in various organs. Aberrations in the T lymphocyte compartment and dysregulated cytokine production are key features of SLE pathogenesis and disease progression. Recently, the role of the interleukin (IL)-17/IL-23 axis in the pathogenesis of SLE has been reported. IL-23 and IL-23R are essential for expansion of pathogenic IL-17-producing T lymphocytes and have been shown to be important in the pathogenesis of lupus in animal models. In this study, the expression of IL-23R and IL-17 in CD4+ and CD8+ T lymphocytes in peripheral blood mononuclear cells (PBMCs) of SLE patients and control subjects were examined by flow cytometry. Twenty-nine SLE patients and 10 control subjects were recruited in this study. Patients were divided into active and inactive groups based on the SLE disease activity index (SLEDAI). As another disease control population, five psoriatic patients
The National Institute of Allergy and Infectious Diseases has awarded a grant to Progentec to fast-track research into new tests for measuring systemic lupus erythematosus disease activity.
INTRODUCTION: Pulmonary arterial hypertension is a complication of systemic lupus erythematosus. Mortality in pregnant patients with pulmonary arterial hypertension related to connective tissue disease is as high as 56%. The authors report the first case of a successful maternal-fetal outcome in a pregnant patient with systemic lupus erythematosus-associated pulmonary arterial hypertension treated with sildenafil and inhaled iloprost during pregnancy and until several weeks after caesarean section. CASE PRESENTATION: The case presented is of a 29-year-old woman with systemic lupus erythematosus and associated severe pulmonary arterial hypertension. Vasodilator therapy with bosentan and sildenafil, immunosuppressive therapy with prednisone, hydroxychloroquine and azathioprine and oral anticoagulation (phenprocoumon) had normalized her right ventricular over right atrial pressure when she was diagnosed in her 5th week of pregnancy. The teratogenic drugs bosentan and phenprocoumon were stopped, the ...
The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 Classification Criteria for systemic lupus erythematosus (SLE) have been validated with high sensitivity and specificity. We evaluated the performance of the new criteria with regard to disease duration, sex and race/ethnicity, and compared its performance against the Systemic Lupus International Collaborating Clinics (SLICC) 2012 and ACR 1982/1997 criteria.Twenty-one SLE centres from 16 countries submitted SLE cases and mimicking controls to form the validation cohort. The sensitivity and specificity of the EULAR/ACR 2019, SLICC 2012 and ACR 1982/1997 criteria were evaluated.The cohort consisted of female (n=1098), male (n=172), Asian (n=118), black (n=68), Hispanic (n=124) and white (n=941) patients; with an SLE duration of 1 to ,3 years (n=196) and ≥5 years (n=879). Among patients with 1 to ,3 years disease duration, the EULAR/ACR criteria had better sensitivity than the ACR criteria (97% vs 81%). The ...
Introduction: Neuropsychiatric systemic lupus erythematosus is often clinically challenging to diagnose, treat and monitor. Although brain magnetic resonance imaging is frequently performed before lumbar puncture in neuropsychiatric systemic lupus erythematosus, it is not clear from the literature whether specific brain magnetic resonance imaging findings are associated with distinct clinical features of neuropsychiatric systemic lupus erythematosus. Methods: We conducted a systematic review and meta-analysis on published studies of neuropsychiatric systemic lupus erythematosus including brain magnetic resonance imaging and the 1999 American College of Rheumatology-defined clinical neuropsychiatric systemic lupus erythematosus syndromes to determine their relationship. Pooled prevalence and risk ratio for distinct neuropsychiatric systemic lupus erythematosus associations were determined with 95% confidence intervals. Results: Of 821 studies screened, 21 fulfilled inclusion criteria. A total of ...
Neuropsychiatric systemic lupus erythematosus (NP-SLE) is one of the major cause of morbidity in systemic lupus erythematosus patients and its treatment depends on identification of pathogenic mechanisms. We describe the rare case of neuropsychiatric systemic lupus erythematosus (NP-SLE) complicated by pericardial effusion combined to low C4 level persisting and hyperprolactinaemia. A cyclophosphamide therapy showed a good response in a 21-year old woman with disturbances in thought processes and an acute confusional state with sierositis. This paper confirms that a cyclophosphamide therapy contributes to control a disease activity by a mechanism of prolactin level reduction. Other studies occur to evaluate this hypothesis.
Signs of Bullous systemic lupus erythematosus including medical signs and symptoms of Bullous systemic lupus erythematosus, symptoms, misdiagnosis, tests, common medical issues, duration, and the correct diagnosis for Bullous systemic lupus erythematosus signs or Bullous systemic lupus erythematosus symptoms.
A family is reported in which two siblings had congenital complete heart block with resultant congestive heart failure, the father and paternal grandfather show adult-onset conduction defects, and the mother has systemic lupus erythematosis. The interaction of heredity and environment is discussed in this context. A review of the literature on familial complete heart block suggests that so-called pure congenital-onset familial heart block, originally felt to be genetic, may in fact have an important enivronmental component, specifically related to ongoing maternal factors such as systemic lupus erythematosis. ...
TY - JOUR. T1 - Effect of plasmapheresis on T and B lymphocyte functions in patients with systemic lupus erythematosus. T2 - A double blind study. AU - Tsokos, G. C.. AU - Balow, J. E.. AU - Huston, David P.. AU - Wei, N.. AU - Decker, J. L.. PY - 1982/7/13. Y1 - 1982/7/13. N2 - Nine patients with active systemic lupus erythematosus entered a double-blind randomized trial to study the therapeutic effect of vigorous versus sham reinfusion plasmapheresis. Four of them received real plasmapheresis while five received sham reinfusion plasmaphersis. In the present communication we report the effects of these procedures on T lymphocytes in peripheral mononuclear cells, proliferative responses to mitogens, allogeneic mixed lymphocyte reaction and cell-mediated lympholysis, as well as the effect of plasmapheresis on the spontaneous and pokeweed mitogen induced immunoglobulin secreting cells in peripheral blood. Several mononuclear cell functions were abnormal at the beginning of the study but no ...
To date, the association of serum macrophage migration inhibitory factor (MIF) and serum adipokines with lupus nephritis is controversial. To assess the utility of serum MIF, leptin, adiponectin and resistin levels as markers of proteinuria and renal dysfunction in lupus nephritis. Cross-sectional study including 196 systemic lupus erythematosus (SLE) patients and 52 healthy controls (HCs). Disease activity was assessed by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Renal SLE involvement was investigated by renal-SLEDAI. MIF, adiponectin, leptin and resistin levels were quantified by ELISA. We assessed the correlations of quantitative variables by Spearman correlation (rs). Multivariable linear regression adjusted the variables associated with the severity of proteinuria. SLE patients had higher MIF (p = 0.02) and adiponectin (p | 0.001) than HCs. Patients with renal SLE involvement (n = 43) had higher adiponectin (19.0 vs 13.3 μg/mL, p = 0.002) and resistin (10.7 vs 8.9 ng/mL, p = 0
TY - JOUR. T1 - Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus Erythematosus. AU - Escalante, Agustín. AU - L. Brey, Robin. AU - D.Mitchell Jr., Braxton. AU - Dreiner, Ute. PY - 1995/6. Y1 - 1995/6. N2 - objective: To measure the accuracy of anticardiolipin antibodies (aCL) in identifying a history of thrombosis among patients with systemic lupus erythematosus (SLE) or the primary antiphospholipid syndrome (PAPS). patients and methods: Patients with SLE or PAPS who attended our rheumatology clinic between April 1992 and March 1994 were included in a retrospective analysis of the relationship between thrombotic events and aCL. All aCL measurements were performed in the same laboratory by enzyme-linked immunosorbent assay, blinded as to the presence or absence of thrombosis. The diagnostic accuracy of IgG, IgM, and IgA aCL was quantified by means of the receiver operating characteristic area under the curve (ROC AUC) for each ...
A patient is described in which an inherited defect in the synthesis of C2 complement component coexisted with the disease systemic lupus erythematosus. The family studies show evidence of the autosomal recessive nature of the inheritance of the C2 synthesis defect. Of particular interest was the finding of a great-aunt who also had homozygous C2 deficiency. This great-aunt suffered from discoid lupus erythematosus as well. The occurrence of various autoantibodies in the serum from the family members, the typing for blood groups, HL-A antigens, and some serum protein markers are reported and discussed. The C2 deficiency may be a critical defect in the host defenses to infection that predisposed to the development of autoimmune disease. ...
A case of a 42-year-old female with hyperthyroidism was subsequently diagnosed to have systemic lupus erythematosus with distal RTA. The clinical examination on admission showed swelling of the knee joints and the urinalysis showed pH 6.5, pro 3+. Her blood routine results were as follows: white blood cells 1.85×109/L, platelets 100×109/L, erythrocyte 3.06×1012/L. The serum potassium was 3.11 mmol/L, 24 hour urinary electrolyte: K 68.87 mmol/24 H, antinuclear antibodies (ANA) 1:1 000, speckled pattern. The anti-double stranded DNA antibody (anti-dsDNA), anti SS-A(52) antibody and anti SS-A(60) antibody were positive. The light microscopy and immunofluorescence showed diffuse proliferative lupus nephritis. These data were compatible with the diagnosis of systemic lupus erythematosus. The diagnosis of hyperthyroidism and distal RTA is clear. This report showed that other autoimmune disease in the diagnosis of hyperthyroidism should not be ignored.. ...
Background and Objectives: Belimumab (BEL) is a monoclonal antibody approved for the treatment of active systemic lupus erythematosus (SLE) but not for lupus nephritis (LN) and neuropsychiatric systemic lupus erythematosus (NPSLE). We aimed to assess BELs effects on these severe, potentially life-threatening manifestations.Methods: Retrospective observational cohort study using routine clinical data in a case series of patients with SLE receiving BEL.Results: Sixteen patients received BEL therapy for active SLE. Nine were excluded because they had no LN or NPSLE. Six suffered from LN, and one patient had NPSLE. All LN patients received BEL in addition to standard therapy including glucocorticoids, hydroxychloroquine, and mycophenolate mofetil in five cases, and tacrolimus in one case. Three patients with proteinuria >1,000 mg/g creatinine responded well (one complete, two partial renal responses); all other patients had decreasing proteinuria and a reduction in anti-dsDNA levels. The patient with NPSLE
TY - JOUR. T1 - A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan. AU - Weng, C. T.. AU - Chung, T. J.. AU - Liu, M. F.. AU - Weng, M. Y.. AU - Lee, C. H.. AU - Chen, J. Y.. AU - Wu, A. B.. AU - Lin, B. W.. AU - Luo, C. Y.. AU - Hsu, S. C.. AU - Lee, B. F.. AU - Tsai, H. M.. AU - Chao, S. C.. AU - Wang, J. Y.. AU - Chen, T. Y.. AU - Chen, C. W.. AU - Chang, H. Y.. AU - Wang, C. R.. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Since large-scale reports of pulmonary infarction in systemic lupus erythematosus (SLE) are limited, a retrospective study was performed for this manifestation in 773 hospitalized patients in southern Taiwan from 1999 to 2009. Pulmonary infarction was defined as the presence of pulmonary embolism, persistent pulmonary infiltrates, and characteristic clinical symptoms. Demographic, clinical, laboratory, and radiological images data were analyzed. There were 12 patients with pulmonary embolism and 9 of them had ...
TY - JOUR. T1 - Cochlear Histopathologic Findings in Patients With Systemic Lupus Erythematosus. T2 - A Human Temporal Bone Study. AU - Kariya, Shin. AU - Kaya, Serdar. AU - Hizli, Ömer. AU - Hizli, Pelin. AU - Nishizaki, Kazunori. AU - Paparella, Michael M.. AU - Cureoglu, Sebahattin. PY - 2016/4/2. Y1 - 2016/4/2. N2 - HYPOTHESIS:: We hypothesized that, in archived human temporal bone samples from patients with systemic lupus erythematosus (SLE), a pathologic condition exists in the stria vascularis and cochlear hair cells. BACKGROUND:: Sensorineural hearing loss is a common feature in SLE patients. However, the pathophysiologic mechanism of cochlear dysfunction is unclear. METHODS:: We examined 15 temporal bone samples from 8 SLE patients, along with 17 samples from 10 age-matched healthy control patients. The samples were serially sectioned in the horizontal plane and stained with hematoxylin and eosin. We determined the area of the stria vascularis in a midmodiolar section of each cochlear ...
TY - JOUR. T1 - Autoimmune hepatitis with raised alpha-fetoprotein level as the presenting symptoms of systemic lupus erythematosus. T2 - A case report. AU - Liu, Feng Cheng. AU - Chang, Deh Ming. AU - Lai, Jenn Haung. AU - Lin, Chih Kung. AU - Chen, Hsiang Cheng. AU - Hou, Tsung Y.. AU - Kuo, San Yuan. PY - 2007/3/1. Y1 - 2007/3/1. N2 - Systemic lupus erythematosus (SLE) and autoimmune hepatitis are distinct clinical disorders, which rarely occur, in the same patient. We describe a 59-year-old woman with coexistence of both conditions. Photosensitivity, arthritis, positive ANA, and extreme elevation of anti-dsDNA concluded the diagnosis of SLE. Hyperbilirubinemia, high serum value of liver function, and elevation of alpha-fetoprotein were also prominent. By a review of pertinent literature, clinical investigation, calculation of autoimmune hepatitis score, and pathology of liver biopsy specimen, we were in favor of autoimmune hepatitis. Awareness of this rare presentation may be beneficial to ...
TY - JOUR. T1 - Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. AU - Hall, S.. AU - McCormick, J. L.. AU - Greipp, P. R.. AU - Michet, C. J.. AU - McKenna, C. H.. PY - 1985/1/1. Y1 - 1985/1/1. N2 - Fourteen patients with systemic lupus erythematosus had splenectomies done between 1960 and 1982 for treatment of severe thrombocytopenia. Thrombocytopenia persisted or recurred within 1 month postoperatively in five patients and within 6 months in three others. Three patients had late recurrence (18, 30, and 54 months after splenectomy); in two cases it was probably related to withdrawal of immunosuppressive agents or corticosteroids. Median lowest platelet count before splenectomy and median platelet count at relapse or failure of splenectomy were both 8000/μL. Only two patients maintained normal platelet counts without need for corticosteroids or other treatment. These results differ from those in patients with idiopathic thrombocytopenic purpura. Other treatments ...
TY - JOUR. T1 - Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus. T2 - A double blind, placebo controlled pilot study. AU - Tam, Lai S.. AU - Li, Edmund K.. AU - Leung, Vivian Y.F.. AU - Griffith, James F.. AU - Benzie, Iris F.F.. AU - Lim, Pak L.. AU - Whitney, Bruce. AU - Lee, Vivian W.Y.. AU - Lee, Kenneth K.C.. AU - Thomas, G. Neil. AU - Tomlinson, Brian. N1 - Copyright: Copyright 2010 Elsevier B.V., All rights reserved.. PY - 2005/2. Y1 - 2005/2. N2 - Objective. Patients with systemic lupus erythematosus (SLE) experience excess morbidity and mortality due to coronary artery disease (CAD) that cannot be fully explained by the classical CAD risk factors. Among emerging CAD risk factors, oxidative stress is currently being emphasized. We evaluated the effects of longterm antioxidant vitamins on markers of oxidative stress and antioxidant defense and endothelial function in 39 patients with SLE. Methods. Patients were ...
Title:Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus. VOLUME: 16 ISSUE: 2. Author(s):Johanna Pedroza-Díaz*, Tania Paola Luján Chavarria, Carlos Horacio Muñoz Vahos, Diego Francisco Hernández Ramírez, Elizabeth Olivares-Martínez, Gloria Vásquez, Luis Llorente, Hilda Fragoso-Loyo, Sarah Röthlisberger and Blanca Lucía Ortiz Reyes. Affiliation:Instituto Tecnologico Metropolitano-ITM-, Facultad de Ciencias Exactas y Aplicadas, Grupo de Investigacion e Innovacion Biomedica GI2B, Medellín, Universidad de Antioquia, Facultad de Medicina, Grupo de Inmunologia Celular e Inmunogenetica-GICIG-, Medellin, Universidad de Antioquia, Facultad de Medicina, Grupo de Reumatologia Universidad de Antioquia - GRUA-, Medellín, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Department of Immunology & Rheumatology, Mexico DF, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Department of Immunology & ...
TY - JOUR. T1 - Hypercementosis. T2 - A rare finding in a patient with systemic lupus erythematosus. AU - Shoor, Hitesh. AU - Sujir, Nitha. AU - Mutalik, Sunil. AU - Pai, Keerthilatha M.. PY - 2014/11/26. Y1 - 2014/11/26. N2 - Hypercementosis is excessive deposition of non-neoplastic cementum over normal root cementum, which alters root morphology. This cementum may be either hypocellular or cellular in nature. The aetiopathogenesis of hypercementosis is ambiguous. Although most of the cases are idiopathic, several local and systemic factors are also linked to this condition, such as Pagets disease, acromegaly, vitamin A deficiency, etc. We report two rare cases of hypercementosis associated with systemic lupus erythematosus, not previously described in the literature, and also discuss the possible aetiopathogenesis.. AB - Hypercementosis is excessive deposition of non-neoplastic cementum over normal root cementum, which alters root morphology. This cementum may be either hypocellular or ...
Discusses lupus, an autoimmune disorder. Focuses on systemic lupus erythematosus (SLE). Covers symptoms and how it is diagnosed. Covers treatment with medicines like corticosteroids, NSAIDs, and antimalarials. Discusses the importance of good self-care.
Neuropsychiatric symptoms affect nearly half of the patients with systemic lupus erythematosus; however, the effect on disease severity, quality of life, and prognosis is tremendous. Symptoms of neuropsychiatric systemic lupus erythematosus may range from mild diffuse ones, to acute life threatening events. Although the underlying mechanisms are still largely unraveled, several pathogenic pathways are identified, such as antibody-mediated neurotoxicity, vasculopathy due to anti-phospholipid antibodies and other mechanisms, and cytokine-induced neurotoxicity. In the current review, we describe the old and the new regarding epidemiology, pathophysiology, diagnosis, and management of neuropsychiatric systemic lupus erythematosus. The possible link between neuropsychiatric symptoms and specific mechanisms may help to facilitate our understanding of the disease in the future, thus allowing for better treatment strategies.
TY - JOUR. T1 - IgG and IgM autoantibody differences in discoid and systemic lupus patients. AU - Chong, Benjamin F.. AU - Tseng, Lin Chiang. AU - Lee, Thomas. AU - Vasquez, Rebecca. AU - Li, Quan Z.. AU - Zhang, Song. AU - Karp, David R.. AU - Olsen, Nancy J.. AU - Mohan, Chandra. PY - 2012/12. Y1 - 2012/12. N2 - Systemic lupus erythematosus (SLE) patients with discoid lupus erythematosus (DLE) were reported to have milder disease. To test this observation, we used sandwich arrays containing 98 autoantigens to compare autoantibody profiles of SLE subjects without DLE (DLE-SLE\+) (N = 9), SLE subjects with DLE (DLE\+SLE+) (N = 10), DLE subjects without SLE (DLE+SLE-) (N = 11), and healthy controls (N = 11). We validated differentially expressed autoantibodies using immunoassays in DLE-SLE+ (N = 18), DLE+SLE+ (N = 17), DLE+SLE-(N = 23), and healthy subjects (N = 22). Arrays showed 15 IgG autoantibodies (10 against nuclear antigens) and 4 IgM autoantibodies that were differentially expressed ...
The purpose of this study was to investigate whether white matter microstructure is altered in patients suffering from systemic lupus erythematosus (SLE), and if so, whether such alterations differed between patients with and without neuropsychiatric symptoms. Structural MRI and diffusion tensor imaging (DTI) were performed in 64 female SLE patients (mean age 36.9 years, range 18.2-52.2 years) and 21 healthy controls (mean age 36.7 years, range 23.3-51.2 years) in conjunction with clinical examination, laboratory tests, cognitive evaluation, and self-assessment questionnaires. The patients were subgrouped according to the American College of Rheumatology Neuropsychiatric Systemic Lupus Erythematosus case definitions into non-neuropsychiatric SLE (nonNPSLE) and neuropsychiatric SLE (NPSLE). Comparisons between the SLE group and healthy controls showed that the mean fractional anisotropy (FA) was significantly reduced in the right rostral cingulum (p = 0.038), the mid-sagittal corpus callosum (CC) ...
Systemic lupus erythematosus (SLE) is a systemic inflammatory disease. Clinically, the distinction between ongoing inflammation attributed to SLE, and organ damage due to medication or co-morbidities remains challenging. In addition, SLE is a heterogeneous disease where the various disease phenotypes complicate the search for biomarkers that adequately reflect disease activity and/or signs of increasing organ damage. The aim of the thesis was to investigate and evaluate potential new biomarkers of disease activity and/or organ damage in SLE patients.. High mobility group box protein-1 (HMGB1) is a nuclear non-histone protein that can shuttle to the cytoplasm, become secreted extracellularly, and participate in systemic inflammation. Administration of monoclonal anti-HMGB1 antibodies has been reported both to attenuate and intensify disease in animal models of arthritis and lupus. In Paper I of the thesis, circulating anti-HMGB1 was found in 23% of the SLE patients and correlated with disease ...
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Elizabeth S. Kotzen, Sanjeet Roy, Koyal JainAntiphospholipid syndrome (APS) and other causes of thrombotic microangiopathy (TMA) negatively impact the renal outcomes of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Here we review the diagnosis and management of occlusive...
TY - JOUR. T1 - Altered type II interferon precedes autoantibody accrual and elevated type i interferon activity prior to systemic lupus erythematosus classification. AU - Munroe, Melissa E.. AU - Lu, Rufei. AU - Zhao, Yan D.. AU - Fife, Dustin A.. AU - Robertson, Julie M.. AU - Guthridge, Joel M.. AU - Niewold, Timothy B.. AU - Tsokos, George C.. AU - Keith, Michael P.. AU - Harley, John B.. AU - James, Judith A.. N1 - Publisher Copyright: © 2016 Published by the BMJ Publishing Group Limited.. PY - 2016/11/1. Y1 - 2016/11/1. N2 - Objectives The relationship of immune dysregulation and autoantibody production that may contribute to systemic lupus erythematosus (SLE) pathogenesis is unknown. This study evaluates the individual and combined contributions of autoantibodies, type I interferon (IFN-α) activity, and IFN-associated soluble mediators to disease development leading to SLE. Methods Serial serum specimens from 55 individuals collected prior to SLE classification (average timespan=4.3a ...
Haque, Sahena, Gordon, Caroline, Isenberg, David, Rahman, Anisur, Lanyon, Peter, Bell, Aubrey, Emery, Paul, McHugh, Neil, Teh, Lee Suan, Scott, David G. I., Akil, Mohamed, Naz, Sophia, Andrews, Jacqueline, Griffiths, Bridget, Harris, Helen, Youseff, Hazem, McLaren, John, Toescu, Veronica, Devakumar, Vinodh, Teir, Jamal and Bruce, Ian N. (2010) Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. Journal of Rheumatology, 37 (2). pp. 322-329. Full text not available from this repository. (Request a copy ...
OBJECTIVE: To determine whether variant alleles in the coding portion of the mannose-binding lectin (MBL) gene are associated with increased susceptibility to systemic lupus erythematosus (SLE) and concomitant infections. METHODS: MBL alleles and serum concentrations were determined by polymerase chain reaction and enzyme-linked immunosorbent assay, respectively, in 91 Danish patients with SLE and in 250 controls. RESULTS: Homozygosity for MBL variant alleles was observed in 7.7% of the SLE patients compared with 2.8% of the controls (P = 0.06), while no difference was seen for heterozygosity (33.0% versus 34.4%). Homozygotes had an increased risk of acquiring serious infections compared with patients who were heterozygous or homozygous for the normal allele (odds ratio 8.6, 95% confidence interval 1.5-47.6, P = 0.01). The time interval from the diagnosis of SLE to the first infectious event was shorter (P = 0.017), and the annual number of infectious events was 4 times higher, among homozygotes (P = 0
1. van Vollenhoven RF, Morabito LM, Engleman EG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol. 1998;25:285-289. 2. van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus. 1999;8:181-187. 3. Mease PJ, Merrill JT, Lahita R, et al. GL701 (prasterone, dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Presented at: The Endocrine Societys 82nd Annual Meeting; June 21-24, 2000; Toronto, Canada.. 4. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97:4279-4284. 5. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women. J Clin ...
This case report finds that anti-type VII collagen autoantibodies can precede the clinical appearance of bullous systemic lupus erythematosus.
A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. Unilateral cataplexy has not been described previously in detail and its association with SLE is unique. The clinical details, investigations, and diagnostic criteria are discussed and a causal relationship between cataplexy and SLE is suggested.. ...
Systemic lupus erythematosus is a rare, chronic autoimmune condition that can affect different parts of the body, such as the kidneys, skin, joints and blood.
Lupus Erythematosus is a chronic autoimmune disease that causes the immune system to attack ones body. The disease is characterized by the inflammation of various healthy tissues and organs in the body, including the joints, skin, kidneys, heart, lungs, blood vessels and brain. The severity of the disease may vary because no two cases of lupus are exactly alike.. What are the different types of Lupus?. Systemic Lupus Erythematosus (SLE) is the type of the disease that can affect many parts of the body. SLE is the most common form of the disease and is most commonly characterized by inflammation to the joints, skin, kidneys, heart, lungs, blood vessels and brain.. Cutaneous Lupus Erythematosus is a chronic skin disorder than can affect the skin. Patients with Cutaneous Lupus develop photosensitivity, hair loss, skin rashes and skin lesions.. Drug-Induced Lupus Erythematosus, like SLE, can affect many parts of the body. However, Drug-Induced Lupus is caused by an overreaction to certain ...
misc{08a586d2-6965-44d0-b083-93b1aacff9f7, author = {Magnusson, V and Zunec, R and Odeberg, J and Sturfelt, Gunnar and Truedsson, Lennart and Alarcon-Riquelme, ME}, issn = {1529-0131}, language = {eng}, number = {4}, pages = {1348--1350}, publisher = {John Wiley & Sons}, series = {Arthritis and Rheumatism}, title = {Polymorphisms of the Fc gamma receptor type IIB gene are not associated with systemic lupus erythematosus in the Swedish population}, url = {http://dx.doi.org/10.1002/art.20151}, volume = {50}, year = {2004 ...
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 is a market research report available at US $2500 for a Single User PDF License from RnR Market Research Reports Library.
JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND , 2019. The authors described a case of Candida parapsilosis cellulitis in a systemic lupus erythematosus patient presented with a clinical of cellulitis unresponsive to antibiotic treatment. Yeast cells and pseudohyphae were seen in tissue biopsy and C. parapsilosis were identified by tissues culture. There was excellent outcome after surgical debridement and antifungal treatment ...
Background: Lupus erythematosus (LE) is a heterogeneous disease ranging from mainly skin-restricted manifestations (discoid LE [DLE] and subacute cutaneous LE) to a progressive multisystem disease (systemic LE [SLE]). Genetic association studies have recently identified several strong susceptibility genes for SLE, including integrin alpha M (ITGAM), also known as CD11b, whereas the genetic background of DLE is less clear. Principal Findings: To specifically investigate whether ITGAM is a susceptibility gene not only for SLE, but also for cutaneous DLE, we genotyped 177 patients with DLE, 85 patients with sporadic SLE, 190 index cases from SLE families and 395 population control individuals from Finland for nine genetic markers at the ITGAM locus. SLE patients were further subdivided by the presence or absence of discoid rash and renal involvement. In addition, 235 Finnish and Swedish patients positive for Ro/SSA-autoantibodies were included in a subphenotype analysis. Analysis of the ITGAM ...
An antinuclear antibody (ANA) test measures the amount and pattern of antibodies in your blood that work against your own body (autoimmune reaction).. The bodys immune system normally attacks and destroys foreign substances such as bacteria and viruses. But in disorders known as autoimmune diseases, the immune system attacks and destroys the bodys normal tissues. When a person has an autoimmune disease, the immune system produces antibodies that attach to the bodys own cells as though they were foreign substances, often causing them to be damaged or destroyed. Rheumatoid arthritis and systemic lupus erythematosus are examples of autoimmune diseases.. An ANA test is used along with your symptoms, physical examination, and other tests to find an autoimmune disease.. ...
Looking for online definition of malar rash in the Medical Dictionary? malar rash explanation free. What is malar rash? Meaning of malar rash medical term. What does malar rash mean?
Objective: An Italian multicentre study was promoted in order to assess the accuracy of four anti-double-stranded DNA (dsDNA) antibody assays for SLE diagnosis and monitoring. Methods: Two hundred and twenty-three patients with established SLE according to ACR classification criteria were enrolled from 9 centres. They included 59 patients at first evaluation (disease duration ,12 months) and 164 with longer disease duration (median disease duration 120 months). The sera from 55 healthy subjects and 161 patients with rheumatic, infectious or neoplastic diseases were tested as controls. SLE activity was measured by ECLAM score. Anti-dsDNA antibodies were detected in serum by means of FarrzymeTM assay, fluoroenzymeimmunoassay (EliATM), Crithidia luciliae indirect immunofluorescence (CLIFT) or Farr radioimmunoassay (Farr). Cut-off values of quantitative assays were chosen by ROC curves analysis. Statistics were conducted by SPSS software package. Results: Sensitivity for SLE diagnosis ranged between ...
TY - JOUR. T1 - Total knee replacement in a patient with lupus anticoagulant.. AU - Bhagia, U. T.. AU - Corpe, Raymond S. AU - Steflik, D.. PY - 1997/1/1. Y1 - 1997/1/1. N2 - The lupus anticoagulant is an acquired circulating anticoagulant that was first described in patients with systemic lupus erythematosus (SLE). This rare hematologic entity is seen in about 1% to 2% of the general population and about 10% to 35% of the patients with SLE. Although associated with a prolonged partial thromboplastin time (PTT), the lupus anticoagulant does not cause bleeding complications but may be associated with an increase in thromboembolic complications. This report is presented to alert orthopedic surgeons of the increased risk of thromboembolic disease with a paradoxically prolonged PTT in patients with the lupus anticoagulant.. AB - The lupus anticoagulant is an acquired circulating anticoagulant that was first described in patients with systemic lupus erythematosus (SLE). This rare hematologic entity ...
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies Elvira Bangert,1 Laura Wakani,2 Mehveen Merchant,3 Vibeke Strand,4 Zahi Touma2 1Division of Rheumatology, Department of Medicine, Queen’s University, Kingston, ON, Canada; 2University of Toronto Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto, ON, Canada; 3Division of Rheumatology, Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada; 4Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune, multisystem rheumatic disease with significant impact on health-related quality of life (HRQoL). Patient-reported outcomes (PROs) provide valuable data on patient perceptions across a variety of domains, such as HRQoL, pain, fatigue, and depression. The measurement and results of PROs with respect to HRQoL in randomized controlled trials
Genetic epistasis of IL23/IL17 pathway genes in Crohns disease. [PMID 19306001] No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus. [PMID 19522770] Variants of the IL23R gene are associated with ankylosing spondylitis but not with Sjogren syndrome in Hungarian population samples. [PMID 19757086] Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients. [PMID 19916168 ...